CF
VRTX icon

Cantor Fitzgerald’s Vertex Pharmaceuticals VRTX Stock Holding History

Cantor Fitzgerald’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,000
Closed -$1.61M – 397
2024
Q4 		$1.61M Buy
+4,000
New +$1.85M 0.03% 72

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cantor Fitzgerald's VRTX Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 35,945 shares — an estimated $12.5M sold.

Cantor Fitzgerald first reported a position in VRTX in Q4 2022 and held it in 4 quarters. The position peaked at $12.5M in Q3 2023. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Cantor Fitzgerald reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 35,945 Vertex Pharmaceuticals shares in Q4 2023, an estimated $12.5M.
  • Cantor Fitzgerald first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Cantor Fitzgerald's Vertex Pharmaceuticals position peaked at $12.5M in Q3 2023.
  • 1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.